2DAVIES L, WELCH H G. Increasing incidence of thyroid cancer in the United States, 1973-2002 [ J ] . JAMA, 2006, 295(18): 2164-2167.
3JONKLAAS J, SARLIS N J, LITOFSKY D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy [ J ] . Thyroid, 2006, 16(12):1229-1242.
4KIM S S, LEE B J, LEE J C, et al. Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience [ J ] . Endocrine, 2011, 39(3): 259-265.
5JIN J, MACHEKANO R, MCHENRY C R. The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease [ J ] . Am J Surg, 2010, 199(3): 294-297.
6JONKLAAS J, NSOULI-MAKTABI H, SOLDIN S J. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer [ J ] . Mary Ann Liebert, Inc, 2008, 18(9): 943-952.
7HAYMART M R, REPPLINGER D, LEVERSON G E, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage [ J ] . J Clin Endocrinol Metab, 2008, 93(3): 809-814.
